PortalPublikationenLiquid biopsy: novel technologies and clinical applications

Liquid biopsy: novel technologies and clinical applications

Standard

Liquid biopsy: novel technologies and clinical applications. / Reimers, Natalie; Pantel, Klaus.

in: CLIN CHEM LAB MED, Jahrgang 57, Nr. 3, 25.02.2019, S. 312-316.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Reimers, N & Pantel, K 2019, 'Liquid biopsy: novel technologies and clinical applications', CLIN CHEM LAB MED, Jg. 57, Nr. 3, S. 312-316. https://doi.org/10.1515/cclm-2018-0610

APA

Reimers, N., & Pantel, K. (2019). Liquid biopsy: novel technologies and clinical applications. CLIN CHEM LAB MED, 57(3), 312-316. https://doi.org/10.1515/cclm-2018-0610

Vancouver

Reimers N, Pantel K. Liquid biopsy: novel technologies and clinical applications. CLIN CHEM LAB MED. 2019 Feb 25;57(3):312-316. https://doi.org/10.1515/cclm-2018-0610

Bibtex

@article{fb174b8a2a9646d49f7f27226a996f78,
title = "Liquid biopsy: novel technologies and clinical applications",
abstract = "{"}Liquid biopsy{"} was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.",
keywords = "Journal Article",
author = "Natalie Reimers and Klaus Pantel",
year = "2019",
month = feb,
day = "25",
doi = "10.1515/cclm-2018-0610",
language = "English",
volume = "57",
pages = "312--316",
journal = "CLIN CHEM LAB MED",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "3",

}

RIS

TY - JOUR

T1 - Liquid biopsy: novel technologies and clinical applications

AU - Reimers, Natalie

AU - Pantel, Klaus

PY - 2019/2/25

Y1 - 2019/2/25

N2 - "Liquid biopsy" was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.

AB - "Liquid biopsy" was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.

KW - Journal Article

U2 - 10.1515/cclm-2018-0610

DO - 10.1515/cclm-2018-0610

M3 - SCORING: Journal article

C2 - 30465714

VL - 57

SP - 312

EP - 316

JO - CLIN CHEM LAB MED

JF - CLIN CHEM LAB MED

SN - 1434-6621

IS - 3

ER -